Arcus Biosciences, Inc. is a company in the U.S. stock market and it is a holding in 47 U.S.-traded ETFs. RCUS has around 5.0M shares in the U.S. ETF market. The largest ETF holder of RCUS is the SPDR S&P Biotech ETF (XBI), with approximately 1.87M shares. Investors may also find of interest that the ETF with the largest allocation to RCUS stock is Loncar Cancer Immunotherapy ETF (CNCR), with a portfolio weight of 4.03%. On average, U.S. ETFs allocate 0.21% of RCUS to their portfolios.
Additionally, RCUS is a favorite stock for Vanilla and Active ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with RCUS as a holding is the ProShares UltraPro Russell2000 (URTY), with a return of 167.77%.